March/April 2013

Breast cancer clinicians today are faced with an ever-expanding number of older patients, yet determining the most appropriate treatment for these individuals can be challenging.

Despite progress in treating chemotherapy-induced nausea and vomiting, especially in the acute phase up to 24 hours after treatment, the condition is still one of the side effects patients fear most.

The majority of the new oncology drugs approved in 2012 are oral agents, and by reviewing the indications for these agents, it's easy to see how genetics impacts the agent's efficacy.

Due to the high lifetime risk of ovarian cancer and the poor ovarian cancer surveillance options available, women who carry BRCA1 or BRCA2 mutations are advised to remove their ovaries and fallopian tubes by age 40 or when childbearing is complete.

Three oncology nurses at the Smilow Cancer Hospital at Yale-New Haven write about the Smilow Society, an interactive and innovative journal club enabling nurses to stay abreast of important research developments, which can then be translated directly into clinical practice.

Sandra Spoelstra, PhD, RN, of the Michigan State University College of Nursing, outlines the essential and growing role of oncology nurses in helping patients with cancer to manage their oral regimens

J. Michael Dixon, MD, describes a number of effective options for clinicians to help patients better manage menopausal symptoms in patients with breast cancer and improve their quality of life.

A review of several studies examining the long-term benefits of breast-conservation therapy compared with mastectomy for women with stage breast cancer.